Randomized, controlled trial of telcagepant for the acute treatment of migraine

What Was Tested

This randomized controlled trial paper looks at CGRP (Calcitonin Gene-Related Peptide) in the context of migraine.

The neuropeptide calcitonin gene-related peptide (CGRP) plays a key role in migraine pathophysiology.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this CGRP (Calcitonin Gene-Related Peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on CGRP (Calcitonin Gene-Related Peptide), so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with CGRP (Calcitonin Gene-Related Peptide) could be set against what happens without it.

The 5 co-primary endpoints were pain freedom, pain relief, and absence of photophobia, absence of phonophobia, and absence of nausea, all at 2 hours postdose.

The key secondary endpoint was 2-24 hour sustained pain freedom.

Tolerability was assessed by adverse experience reports.

What Was Measured

PubMed files the paper under topics including Acute Disease, Azepines, Calcitonin Gene-Related Peptide, Calcitonin Gene-Related Peptide Receptor Antagonists, Endpoint Determination, Hyperacusis and Imidazoles.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of CGRP (Calcitonin Gene-Related Peptide) in people with migraine.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2009 (Neurology), a journal based in United States.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.